Mark L Hartman Selected Research

Mark L Hartman Research Topics

4	Type 2 Diabetes Mellitus (MODY) 01/2020 - 01/2016
3	Non-alcoholic Fatty Liver Disease 01/2020 - 11/2017
3	Body Weight (Weight, Body) 01/2008 - 07/2004
2	Pituitary Diseases (Disease, Anterior Pituitary) 01/2007 - 05/2002
1	Fibrosis (Cirrhosis) 01/2020
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2018
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 11/2017
1	Hypoglycemia (Reactive Hypoglycemia) 01/2016
1	Liver Diseases (Liver Disease) 01/2007
1	Hypothyroidism 01/2007
1	Malnutrition (Nutritional Deficiencies) 01/2007
1	Hypopituitarism (Sheehan's Syndrome) 09/2003
1	Obesity 01/2002

3	Insulin (Novolin)FDA Link 01/2018 - 01/2016
2	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 01/2016
2	basal insulin peglisproIBA 01/2018 - 01/2016
2	Insulin Glargine (Lantus)FDA Link 01/2018 - 01/2016
2	Insulin-Like Growth Factor I (IGF-1)IBA 05/2007 - 01/2007
2	Growth Hormone (Somatotropin)IBA 07/2004 - 09/2003
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	Glucagon-Like Peptide-1 ReceptorIBA 01/2020
1	Peptides (Polypeptides)IBA 01/2020
1	tirzepatideIBA 01/2020
1	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2020
1	Keratin-18 (Keratin 18)IBA 01/2018
1	InsulinsIBA 01/2018
1	Transaminases (Aminotransferases)IBA 01/2016
1	Hemoglobins (Hemoglobin)IBA 01/2016
1	Triglycerides (Triacylglycerol)IBA 01/2016
1	Hypoglycemic Agents (Hypoglycemics)IBA 01/2016
1	Estrogens (Estrogen)FDA Link 05/2002
1	Hormones (Hormone)IBA 05/2002
1	SecretagoguesIBA 01/2002

3	Therapeutics 11/2017 - 07/2004
1	Glycemic Control 01/2016